Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Forte Biosciences Inc (FBRX)

Forte Biosciences Inc (FBRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 28,273
  • Shares Outstanding, K 1,462
  • Annual Sales, $ 0 K
  • Annual Income, $ -31,480 K
  • EBIT $ -36 M
  • EBITDA $ -36 M
  • 60-Month Beta 1.11
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.91

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 257.24%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 1,320.58% on 03/11/24
  • IV Low 0.00% on 12/18/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 10
  • Volume Avg (30-Day) 70
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 490
  • Open Int (30-Day) 179

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -4.55
  • Number of Estimates 1
  • High Estimate -4.55
  • Low Estimate -4.55
  • Prior Year -1.00
  • Growth Rate Est. (year over year) -355.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.11 +91.29%
on 11/21/24
28.68 -32.57%
on 12/06/24
+5.79 (+42.73%)
since 11/20/24
3-Month
4.11 +370.56%
on 11/01/24
28.68 -32.57%
on 12/06/24
+12.26 (+173.16%)
since 09/20/24
52-Week
4.11 +370.56%
on 11/01/24
28.68 -32.57%
on 12/06/24
+0.84 (+4.54%)
since 12/20/23

Most Recent Stories

More News
5 Stocks Retail Investors Are Most Bullish On At Mid-Day

Retailers went overboard about a couple of biotech stocks and a MedTech name, among others on Wednesday.

FBRX : 19.34 (+3.64%)
QSI : 1.3000 (+0.78%)
DUOT : 5.70 (+26.39%)
IBB : 132.73 (+1.16%)
SLXN : 2.44 (+0.83%)
SPY : 591.15 (+1.20%)
XBI : 91.28 (+1.64%)
ZIM : 18.29 (-0.49%)
Forte Biosciences Stock More Than Doubles On Oversubscribed $53M Private Placement: Retail Goes Wild

The funds will support clinical development of FB102, Forte’s proprietary anti-CD122 monoclonal antibody targeting autoimmune and autoimmune-related diseases.

FBRX : 19.34 (+3.64%)
VXF : 192.94 (+1.36%)
VTI : 293.28 (+1.14%)
ONEQ : 77.21 (+0.86%)
MindMed Sends Letter to Shareholders Highlighting Company’s Positive Momentum and Value-Enhancing Strategy

The Board of Directors (the “Board”) of Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product...

MMED.NE : 14.9000 (+9.48%)
MNMD : 7.16 (+2.07%)
INCY : 68.84 (+2.65%)
SGEN : 228.74 (-0.07%)
PFE : 26.36 (+2.29%)
FBRX : 19.34 (+3.64%)
JAZZ : 122.97 (+0.10%)
ALC : 84.76 (+0.69%)
MindMed Files Preliminary Proxy Statement for 2023 Annual Meeting

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders,...

MMED.NE : 14.9000 (+9.48%)
MNMD : 7.16 (+2.07%)
INCY : 68.84 (+2.65%)
BMY : 57.33 (+1.83%)
SGEN : 228.74 (-0.07%)
FBRX : 19.34 (+3.64%)
Forte Biosciences, Inc. Announces Full Year 2022 Results and Provides Business Update

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced full year 2022 results and provided a business update.

FBRX : 19.34 (+3.64%)
Mr. David Gryska Appointed to Forte Biosciences Board of Directors

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), announced today that Mr. David Gryska has been appointed to the Forte Biosciences Board of Directors.

FBRX : 19.34 (+3.64%)
Forte Biosciences, Inc. Announces Third Quarter 2022 Results and Provides Business Update

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced third quarter 2022 results and provided a business update.

FBRX : 19.34 (+3.64%)
Dr. Scott Brun, M.D. Appointed to Forte Biosciences Board of Directors

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), announced today that Dr. Scott Brun, M.D. has been appointed to the Forte Biosciences Board of Directors.

FBRX : 19.34 (+3.64%)
Camac Partners Condemns Forte Biosciences’ Seemingly Defensive and Unjustifiable Capital Raise

Camac Partners, LLC (together with its affiliates, "Camac" or “we”), which is one of the largest shareholders of Forte Biosciences, Inc. (Nasdaq: FBRX) (“Forte” or the “Company”), today expressed...

FBRX : 19.34 (+3.64%)
Forte Biosciences, Inc. Announces Second Quarter 2022 Results and Provides Business Update

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced second quarter 2022 results and provided a business update.

FBRX : 19.34 (+3.64%)

Business Summary

Forte Biosciences Inc. is a clinical stage, dermatology company. It engages in developing biotherapeutic, FB-401, for the treatment of inflammatory skin diseases which is in clinical stage. Forte Biosciences Inc., formerly known as Tocagen Inc., is based in Sherman Oaks, California.

See More

Key Turning Points

3rd Resistance Point 21.49
2nd Resistance Point 20.53
1st Resistance Point 19.93
Last Price 19.34
1st Support Level 18.37
2nd Support Level 17.41
3rd Support Level 16.81

See More

52-Week High 28.68
Last Price 19.34
Fibonacci 61.8% 19.29
Fibonacci 50% 16.40
Fibonacci 38.2% 13.50
52-Week Low 4.11

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar